Cancer Clinical Trial -Seagen -USOR 20344

A phase 2 basket study of tucatinib in combination with trastuzumab in subjects with previously treated, locally advanced unresectable or metastatic solid tumors driven by HER2 alterations.

Drug

Tastuzumab, tucatinib, Fulvestrant

Phase

Phase II

Condition

Cervical

Keywords

Her 2 +